Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV) and Nkarta (NKTX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Achieve Life Sciences (ACHV) and Nkarta (NKTX) with bullish sentiments.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Achieve Life Sciences (ACHV)
In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Achieve Life Sciences, with a price target of $12.00. The company’s shares closed last Monday at $5.33, close to its 52-week high of $5.59.
According to TipRanks.com, Folkes is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Achieve Life Sciences is a Strong Buy with an average price target of $13.20.
See Insiders’ Hot Stocks on TipRanks >>
Nkarta (NKTX)
Mizuho Securities analyst Salim Syed maintained a Buy rating on Nkarta today and set a price target of $12.00. The company’s shares closed last Monday at $2.81, close to its 52-week low of $1.31.
According to TipRanks.com, Syed is a 1-star analyst with an average return of
Nkarta has an analyst consensus of Strong Buy, with a price target consensus of $11.80.
Read More on ACHV:
Disclaimer & DisclosureReport an Issue
- Achieve Life Sciences CRL from FDA cites deficiencies at manufacturing facility
- Achieve Life Sciences Adds Two Independent Board Directors
- Achieve Life Sciences Reaffirmed at Buy as Financing, Leadership Refresh, and Strong Cytisinicline Data Support Unchanged $10 Price Target
- Achieve Life Sciences Charts Delayed Path to Launch
- Achieve Life Sciences files prospectus for resale of shares by holders
